Researchers uncover new cancer cell vulnerability

Researchers uncover new cancer cell vulnerability
Chromosomes (in blue) and their telomores (in red). Credit: Lab of Narenda Wajepeyee, Yale School of Medicine

(Medical Xpress)—Yale School of Medicine and Yale Cancer Center researchers have uncovered a genetic vulnerability of cancer cells that express telomerase—an enzyme that drives their unchecked growth—and showed that telomerase-expressing cells depend upon a gene named p21 for their survival.

Authors found that simultaneous inhibition of both telomerase and p21 inhibited tumor growth in mice. The is overexpressed in over 90% of human cancers, but not in normal cells, and expression of telomerase is necessary to initiate and promote cancer growth. In this study, the Yale team, led by first author Romi Gupta and corresponding author Narendra Wajapeyee of the Department of Pathology, showed how new pharmacological drug combinations can be applied to simultaneously target both telomerase and p21 to induce cell death in telomerase-expressing .

Finally, the authors also showed that their approach is also applicable for p53 mutant cancers if telomerase and p21 inhibition is combined with pharmacological restoration of p53 tumor suppressor activity. The study, which could open doors to novel therapies for telomerase inhibition, appears in the Proceedings of the National Academy of Sciences.

More information: Romi Gupta, Yuying Dong, Peter D. Solomon, Hiromi I. Wettersten, Christopher J. Cheng, JIn-Na Min, Jeremy Henson, Shaillay Kumar Dogra, Sung H. Hwang, Bruce D. Hammock, Lihua J. Zhu, Roger R. Reddel, W. Mark Saltzman, Robert H. Weiss, Sandy Chang, Michael R. Green, and Narendra Wajapeyee. "Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A." PNAS 2014 ; published ahead of print July 14, 2014, DOI: 10.1073/pnas.1411370111

add to favorites email to friend print save as pdf

Related Stories

Protein 'motif' crucial to telomerase activity

Sep 19, 2013

It is difficult to underestimate the importance of telomerase, an enzyme that is the hallmark of both aging and the uncontrolled cell division associated with cancer. In an effort to understand and control ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

14 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

18 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

mrdingdong
not rated yet Jul 18, 2014
This is old news. Actually they tested two vaccine based on Telomerase; Imatelstat and Telovac both of which failed. If anyone has any update let me know.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.